Genfit S.A. (GNFT)

FR — Healthcare Sector
Peers: CYT  ERYP  ELYM  HCWB  MOLN  MNOV  ANEB  CSBR  KROS  JANX  FENC  EWTX  HRMY  AVTE  ADAG  ACRV  RZLT  ANTX 

Automate Your Wheel Strategy on GNFT

With Tiblio's Option Bot, you can configure your own wheel strategy including GNFT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GNFT
  • Rev/Share 2.1883
  • Book/Share 1.3931
  • PB 2.683
  • Debt/Equity 0.8976
  • CurrentRatio 1.2342
  • ROIC 0.2295

 

  • MktCap 186095104.5408
  • FreeCF/Share -0.9792
  • PFCF -3.8248
  • PE 4.9624
  • Debt/Assets 0.4103
  • DivYield 0
  • ROE 0.4511

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
GNFT
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces the filing of its 2024 Universal Registration Document with the Autorité des marches financiers (AMF ; filing n° D.25-0331) and its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission (SEC).

Read More
image for news GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting
GNFT
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025.

Read More
image for news GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting

About Genfit S.A. (GNFT)

  • IPO Date 2019-03-27
  • Website https://www.genfit.com
  • Industry Biotechnology
  • CEO Mr. M. Pascal Prigent
  • Employees 180
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.